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About 1 in 9 women in European and North American populations
may develop breast cancer throughout their life-time, with rates
having increased during the last decades (Philips et al, 1999). Each
year there are approximately 46 000 new cases in Germany
(Beckmann et al, 1997). Several risk factors have been defined
including age, family history, smoking, hormonal factors and radi-
ation exposure (Goss and Sierra, 1998; Olsen et al, 1999; Philips 
et al, 1999; Martin and Weber, 2000). Familiar predisposition
accounts for some 10% of breast cancer, and about half of these
patients are thought to have a mutation in one of two large genes
that function in DNA damage response, BRCA1 and  BRCA2
(Kote-Jarai and Eeles, 1999; Martin and Weber, 2000). 
Bilaterality of cancer, including breast carcinoma, is thought to
be an indicator of a genetic predisposition (Anderson, 1971;
Knudson, 1971), and studies of blood relatives and of twins
affected by breast cancer have corroborated this view (Bernstein 
et al, 1992; Peto and Mack, 2000). Contralateral breast cancer
accounts for about 2–10% of patients (Hislop et al, 1984; Adami 
et al, 1985; Healey et al, 1993; Mose et al, 1995) and is observed at
an annual incidence of approximately 0.7% per year (Peto and
Mack, 2000). The importance of BRCA1 and BRCA2 for the bilat-
eral occurrence of breast cancer has been demonstrated in large
multi-case families where heterozygosity for a BRCA1 or BRCA2
gene mutation strongly predisposes the affected patients towards
the development of a contralateral breast cancer (Ford et al, 1994,
1998; Easton et al, 1995; Robson et al, 1998; Verhoog et al, 1998).
Young age at onset appears to be a significant risk factor for
contralateral breast cancer in the general population (Hislop et al,
1984; Adami et al, 1985) and also within BRCA1 families, where
the risk declines for patients with a postmenopausal primary
tumour (Verhoog et al, 2000). Initial population-based studies of
selected  BRCA1 and  BRCA2 mutations have provided first
evidence for an apparently low proportion of mutation carriers
among patients with bilateral breast cancer when their age at first
onset was higher than 40 years (Eccles et al, 1998; Gershoni-
Baruch et al, 1999). As an attempt to determine more closely the
relative contribution of BRCA1 and BRCA2 mutations to bilateral
breast cancer in relation to age and family history, we have
performed a hospital-based study of the whole coding region of
the BRCA1 and BRCA2 genes in 75 German patients with bilateral
breast cancer, and compared the results with the prevalence of
BRCA1 and BRCA2 mutations in a pairwise-matched cohort of
patients with unilateral breast cancer. 
PATIENTS AND METHODS 
Patients 
During the years 1996–2000, more than 1000 unselected patients
with breast cancer received radiotherapy in the Department of
Radiation Oncology of the Medical School Hannover. The patients
were counselled about the possibility of a genetic predisposition of
breast cancer, and anamneses were taken using questionnaires
with regard to the family history and previous radiation exposure
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of the patients. After written informed consent had been obtained,
blood samples were collected from 1000 participating patients. 75
patients had developed bilateral breast cancer and took part in this
study. This proportion of 7.5% of cases with bilateral disease was
the same as has been previously reported in another series of over
500 German breast cancer patients (Mose et al, 1995), indicating
that our cohort is representative for a hospital-based cancer popu-
lation in Germany. As a comparison group for mutation frequency
determination, we selected 75 patients with unilateral breast
cancer from the total cohort who were pairwise matched with
respect to age and family history at the time of treatment. 
Clinical data of the patients with bilateral breast cancer were
collected and compared with data of the whole series of 1000
breast cancer patients. In 29 patients, bilateral breast cancer
occurred simultaneously. In the other 46 patients, contralateral
breast cancer developed with a median time interval of 7.2 years
(range 1 to 40 years). A time interval of at least 3 years was
observed in 37 patients. The median age at diagnosis of the first
breast cancer was 54 years, compared with 57 years in the total
cohort. 22 patients (29.3%) were younger than 50 years and 9
patients (12%) younger than 40 years at first diagnosis. Self-
reported family history revealed at least one first or second degree
relative with breast cancer in 17 (22.7%) patients and ovarian
cancer in 1 (1.3%) patient, which was not different from the
figures obtained for the total group of unselected breast cancer
patients (n = 1000). 
Breast conservative surgery of the first and second tumour was
performed in 48 (64%) and 65 (86.7%) patients, respectively.
Postoperative radiotherapy was applicated unilaterally in 18
patients (24%) and bilaterally in 57 patients (76%) with a median
total dose of 50 Gy (single dose: 1.8 Gy). Of the latter group 18
patients received radiotherapy simultaneously to both sides
without overlap of treatment fields. The median follow up for the
first and second tumour was 6.3 and 2.5 years, respectively. 10
patients developed local (one patient bilaterally), 1 patient
regional (axillary node) and 1 patient locoregional recurrence after
a median time interval of 24 months. It is noteworthy that 3 of 6
(50%) identified carriers of a pathogenic BRCA1 or 2 mutation
showed local recurrence, whereas this was the case in only 9 of 69
noncarriers (13%). The actuarial locoregional relapse-free survival
– as evaluated by Kaplan–Meier calculations – was significantly
lower (log-rank test, P = 0.0072) for carriers (mean: 55 months,
95% CI: 36–74 months) compared to non-carriers (mean: 408
months, 95% CI: 354–462 months). Local relapse after initial
radiotherapy occurred in 5 patients (5 of 126 irradiated breasts). 3
of these 5 patients (60%) were carriers of a pathogenic BRCA1 or
BRCA2 mutation. Distant metastases developed in 14 patients
(18.7%) with 10 patients having died of their disease at time of
analysis. 
Methods 
EDTA blood samples from peripheral venous blood were collected
from the patients of both groups, and genomic DNA was extracted
from white blood cells according to a standard salting out proce-
dure. PCR conditions were established to separately amplify all
coding exons and exon-flanking intron sequences of both, BRCA1
and  BRCA2 genes to investigate the samples obtained from
patients with bilateral breast cancer (Appendix, Table 1). We
designed a set of 26 primer pairs for the BRCA1 gene and 29
primer pairs for the BRCA2 gene based on the published genomic
sequence (GenBank Acc. No. L78833 for the BRCA1 gene,
Z74739 for the BRCA2 gene). Due to their large size, the coding
sequences of exon 11 of the BRCA1 gene (3.4 kb) and exon 11 of
the BRCA2 gene (4.9 kb) were amplified in overlapping frag-
ments. On the other hand, exons 5 and 6 and exons 23 and 24 of
the BRCA2 gene could be jointly amplified together with their
intervening intron sequences. 
Standard PCR amplifications were performed in 20 µ l reaction
volumes containing 100–200 ng of genomic DNA, 0.2 mM of
each dNTP and 1 Unit Taq DNA polymerase in 1 × reaction buffer
supplied by the manufacturer (USB/Amersham). Final primer
concentrations were 0.5 µ M. As the standard procedure, 37 PCR
cycles were performed with 1 min denaturation at 94˚C, 1 min
annealing, and 1 min elongation at 72˚C. PCR products over 1 kbp
were amplified at an elongation time of 100–150 s, and in 2 cases
(primer pairs BS13/14 and BS15/16) the reaction mix was supple-
mented with 0.1 M betaine and 2% formamide. Some exons could
be amplified and analysed in a duplex PCR format (Appendix,
Table 2). 
Restriction fragments of 150 to 400 bp (Appendix, Table 3)
were subjected to single strand conformation polymorphism
(SSCP) analysis. In brief, the products were separated on a 40 cm
5% non-denaturating polyacrylamide gel at 40 watts for 5 h in a
cold room, and were subsequently visualized by conventional
silver staining. Aberrantly migrating samples were sequenced on
both strands using an ABI-dRhodamine Terminator Cycle
Sequence Kit, and sequencing data were collected and evaluated
on an ABI 310 Genetic Analyzer (Perkin Elmer). Identified vari-
ants were then screened by restriction enzyme-based assays
(Appendix, Table 4a) in both groups of patients. Some tests
required a mismatch primer to create recognition sites for the
respective restriction enzymes (Appendix, Table 4b). In addition,
the common mutations 5382insC and Cys61Gly in the BRCA1
gene and 6174delT in the BRCA2 gene were analysed by restric-
tion enzyme analysis in all patients, and a subset of patients in the
comparison group who had a positive family history of breast
cancer were scanned for mutations in the large exons of BRCA1
(exon 11) and BRCA2 (exons 10 and 11). 
Statistical evaluation was performed using two-sided chi-square
tests. The allele frequencies of truncating mutations were
compared between both groups and results were considered to be
significant for P < 0.05. In addition, the frequencies of missense
substitutions that were found more than once, were compared
between both cohorts and results and were considered to be signif-
icant if P < 0.004, following Bonferroni’s correction for multiple
testing with a number of 12 independent, i.e. unlinked, common
substitutions. 
RESULTS 
All coding exons and flanking intronic regions of the BRCA1 and
BRCA2 genes were amplified by PCR from genomic DNA
samples of 75 patients with bilateral breast cancer and were inves-
tigated by single-strand conformation polymorphism (SSCP) and
sequencing analysis. Detected sequence alterations were subse-
quently confirmed by restriction enzyme analyses and screened in
the comparison cohort of 75 pairwise-matched patients with
unilateral breast cancer. In addition, a screening of the 3 most
common pathogenic mutations as well as a mutation scanning of
the largest exons of the BRCA1 and  BRCA2 genes was also
performed in the comparison cohort (see Patients and Methods
BJOC 01-2016 850-858  10/9/01  2:10 pm  Page 851852 D Steinmann et al
British Journal of Cancer (2001) 85(6), 850–859 © 2001 Cancer Research Campaign
section). A total of 8 different pathogenic BRCA1 and BRCA2 gene
mutations were identified, with 5 heterozygous carriers among the
patients with bilateral breast cancer and 3 heterozygous carriers
among the patients with unilateral breast cancer (Table 1). All 5
mutations of the patients with bilateral breast cancer were small
frameshift deletions of 1–5 basepairs leading to a premature trans-
lation termination codon. 4 truncating mutations (5946delCT,
6174delT, 8138del5, and the new 4772delA mutation) were found
in the BRCA2 gene, and one frameshift deletion (517delTG) was
uncovered in the BRCA1 gene (Figure 1, Table 1). The mutations
in the group of patients with unilateral breast cancer were all in
BRCA1 and include the Cys61Gly substitution of the RING finger
motif, the 5382insC insertion, and a 5-basepair deletion, 3814del5
(Figure 1, Table 1). There was no concordant occurrence of
BRCA1 or BRCA2 mutations in paired samples of our matched
cohorts. The 3814del5 mutation in the BRCA1 gene and the
4772delA mutation in the BRCA2 gene may be confined to the
single families described here since they had not been reported
previously to the Breast cancer Information Core (BIC) database
(http://www.nhgri.nih.gov/Intramural_research/
Lab_transfer/BIC/). 
The clinical characteristics of the mutation carriers are summa-
rized in Table 2. In the study cohort of patients with bilateral
cancer, one carrier of the 6174delT mutation in the BRCA2 gene
had developed a synchronous bilateral breast cancer by the age of
29 years, and she died from metastatic cancer 6 months after diag-
nosis. This patient also had juvenile-onset diabetes as an additional
complication, eventually accelerating the progression of the
disease. Another patient, and her mother, who also had bilateral
breast cancer, were heterozygotes for the 4772delA mutation in the
BRCA2 gene. The younger patient had her first cancer by the age
of 54 years and a contralateral breast tumour by the age of 59,
while her mother developed synchronous bilateral breast cancer by
the age of 73 years as well as a histologically distinct recurrence in
her first breast; she died from her cancer by the age of 79 years
(Table 2). The other 3 BRCA1 or BRCA2 mutation carriers had
developed metachronous contralateral cancer after time intervals
of 2 y, 4.5 y and 12.5 y, respectively (in comparison with a median
Table 1 Mutations of the BRCA1 and BRCA2 genes in patients with
bilateral and unilateral breast cancer 
Gene Exon Mutation Predicted effect Patient no. (status) 
Bilateral Unilateral
BRCA1 5 T300G Cys→ Gly at 61 1 het 
7 517delTG Truncation 1 het 
11 3814del5 Truncation 1 het 
20 5382insC Truncation 1 het 
BRCA2 11 4772delA Truncation 2 het(*) 
11 5946delCT Truncation 1 het 
11 6174delT Truncation 1 het 
17 8138del5 Truncation 1 het 
Identified mutations are designated according to their nucleotide position
within the BRCA1 or BRCA2 cDNA sequences. het: heterozygote. (*): two
4772delA heterozygous patients were mother and daughter, respectively. 
G T  G A T  G A A A A G  A T  C A A A G  A A C C T  A C T  C T
90 100 110
Wild-type control
. . GAT GAA AAG ATC AAA GAA...
G T  G  A T  G A A A  G A A T  N A A G  A A C C T  T N T
100
*
110
4772delA heterozygous
. . GAT GAA AAG ATC AAA GAA...
. . GAT GAA AGA TCA AAG AAC...
A
G G T  A T  A T  T  G T T T A C T T T A C  C A  A  A T  A A C
80 90 100
Wild-type control
G G T A T A T  T  G T T T A C N T T A C  N C  A  T N N N A N G
40 50 60
3814del5 heterozygous
forward: ...TTT  GGT  AAA  GTA  AAC  AAT... wildtype: ...TTT  GGT  AAA  GTA  AAC  AAT...
3814del5: ...TTT  GGT  AAA  GTA  AAC  AAT...
B
*
Figure 1 Identification of new truncating mutations in the BRCA1 and BRCA2 genes. (A) Direct sequencing of BRCA2 mutation 4772delA in a patient with
bilateral breast cancer. Left: wildtype control, right: heterozygous mutation carrier. An asterisk marks the start of the frameshift. (B) Direct sequencing of BRCA1
mutation 3814del5 in a patient with unilateral breast cancer. The antisense strand is shown. Left: wildtype control, right: heterozygous mutation carrier. An
asterisk marks the start of the frameshift 
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interval of 7.2 y in the total cohort). In 3 of the 6 carriers with
bilateral cancer, one of both tumours was multifocal. The family
history of cancer in 1st and 2nd degree relatives was negative for 3
of the 5 unrelated patients who had bilateral cancer and a BRCA1
or BRCA2 truncating mutation. 
Apart from these clearly pathogenic mutations, a further 11 amino
acid variants and polymorphisms were found in the coding region of
the BRCA1 gene and 12 were detected in the BRCA2 gene (Table 3).
Common alterations with more than one occurrence were observed
also in the comparison group, and their allele frequencies were not
significantly different between the patients with bilateral breast
cancer and the patients with unilateral breast cancer. There was no
significant deviation in the genotype frequences from those expected
for Hardy–Weinberg equilibrium. 7 polymorphisms of the BRCA1
gene (2201C/T, 2430T/C, Pro871Leu, Glu1038Gly, Lys1183Arg,
4426C/T, Ser1613Gly) and 3 polymorphisms of the BRCA2 gene
(Asn289His, 1593A/G and Asn991Asp) were in absolute linkage
disequilibrium, in accordance with previous findings in other popula-
tions (Durocher et al, 1996; Dunning et al, 1996; Southey et al, 1999;
Wagner et al, 1999). A slightly higher prevalence of the Gln356Arg
substitution was observed among patients with bilateral cancer (9/75
vs. 6/75, including one patient with unilateral breast cancer carrying
the Cys61Gly mutation in cis with the Arg356 allele), a non-signifi-
cant trend which may deserve further attention in larger cohorts
taking into account that the Arg356 substitution is located within the
ZBRK1-binding region and has recently been described to impair the
BRCA1-mediated induction of GADD45 expression (Zheng et al,
2000). In addition, 2 unclassified missense variants of BRCA2
(Pro1819Ser, Lys2950Asn) were found only in the cohort with bilat-
eral disease, which can not be adequately addressed for their func-
tional impact at the present time. Altogether, despite these subtle
tendencies, the number and frequencies of missense substitutions
did not differ significantly between the 2 cohorts of unilateral and
bilateral breast cancer patients. 
DISCUSSION 
Contralateral breast cancer risk appears to be strongly increased in
multi-case families with a genetic predisposition through BRCA1
and BRCA2 gene mutations (Ford et al, 1994, 1998; Easton et al,
1995; Robson et al, 1998; Verhoog et al, 1998). These may act
in concert with environmental factors such as radiation (Goss
and Serra, 1998; Roberts et al, 1999), as there is accumulating
evidence to implicate the BRCA1 and BRCA2 gene products in the
cellular responses to radiation-induced damage (for review see
Kote-Jarai and Eeles, 1999; Haber, 2000; Welcsh et al, 2000). It
thus seems on solid biochemical grounds to assume that BRCA1
and  BRCA2 mutations predispose towards the development of
bilateral breast cancer via their impairment of DNA repair. On the
other hand, the first population-based studies of a limited number
of BRCA1 and BRCA2 gene mutations have revealed mutations
only in a small minority of patients with bilateral disease, and most
of these also had an early onset at first primary (Eccles et al, 1998;
Gershoni-Baruch et al, 1999). 
To gain more insight into the proportion of bilateral breast cancer
that can be explained by BRCA1 and BRCA2 mutations in a hospital
setting, we analysed the whole BRCA1 and BRCA2 coding region in
75 consecutive patients with bilateral breast cancer not selected for
age or family history. Somewhat unexpectedly, only 5 unrelated
carriers of a truncating mutation were identified. Family history
would not have been a good indicator for BRCA1 or BRCA2 testing
in these cases. Our finding that 3 unrelated patients and one
mother–daughter pair with bilateral breast cancer had frameshift
deletions in their BRCA2 genes, does not support previous
suggestions that BRCA2 mutation carriers may be less prone to
develop a contralateral cancer than BRCA1 mutation carriers
(Verhoog et al, 1999, 2000). However, in view that 4 of the 5
BRCA2 deletion carriers developed their contralateral breast cancer
after a first diagnosis at an age >45 years, it is possible that the age
at first primary could be less influential in case of BRCA2 mutations
than it is for BRCA1 gene mutations (Verhoog et al, 2000). The
higher number of BRCA2 carriers among patients with bilateral
cancer compared with BRCA1 carriers among the patients with
unilateral breast cancer may deserve further investigation but could
also reflect a maldistribution by chance due to the small numbers
involved. 
The proportion of 6.7% BRCA1 and BRCA2 deletion carriers
among the patients with bilateral breast cancer in our study lies
well within the range of 5–10% of breast cancer cases that are
generally assumed to be caused by a strong familiar predisposition
(Kote-Jarai and Eeles, 1999; Martin and Weber, 2000). 3 carriers
(4%) were found also in the comparison group indicating that the
prevalence of ‘classical’ deleterious BRCA1 and BRCA2 mutations
is not significantly different in patients with bilateral and unilateral
disease from the same department matched by age and family
history. We thus investigated whether more common missense
substitutions of BRCA1 or BRCA2 might play a role as predis-
posing factors towards contralateral cancer. Missense substitutions
in other tumour suppressor genes have been described as low-
penetrance mutations that may predispose to certain malignancies
or modify disease progression (Larson et al, 1998; Otterson et al,
1999; Varley et al, 1999; Lumin et al, 2000; Rebbeck et al, 2000),
and a few missense variants of the BRCA1 and BRCA2 proteins,
including the Gln356Arg, Arg841Trp and Leu871Pro substitutions
of BRCA1 and the Asn372His substitution of BRCA2, have previ-
ously been implicated in the susceptibility to breast or ovarian
cancer (Barker et al, 1996; Durocher et al, 1996; Dunning et al,
1996; Healey et al, 2000). However, none of the common BRCA1
and  BRCA2 variants occurred at a significantly increased pre-
valence in our patients with bilateral cancer, nor did we find a
deviation of the genotype distributions from Hardy–Weinberg
equilibrium. Hence, there was no evidence to support a strong
predisposition by any of the common missense substitutions. Our
study had 80% power to detect relative risks of 2.5 or greater for
polymorphisms with an allele frequency of about 0.3, therefore
more subtle effects or moderate risks for less frequent variants
cannot be finally excluded. 
Altogether, these results suggest that patients with bilateral
breast cancer, if not selected for age and family history, are not
significantly more likely to be carriers of a BRCA1 or BRCA2
alteration than patients with unilateral breast cancer. In fact, the
proportion of detected BRCA1 and  BRCA2 mutations among
patients with bilateral disease appeared much lower than would
have been calculated from high-penetrance breast cancer families
(Ford et al, 1994, 1998; Easton et al, 1995). If, for example, a
BRCA1 or BRCA2 mutation confers a risk of about 50% to develop
a contralateral breast cancer by the age of 54, we might have
expected that about 1 in 4 patients with bilateral breast cancer in a
similarly aged population-based cohort were carriers of a BRCA1
or BRCA2 mutation, a proportion to be detected with 80% power
in our study. Instead, our present data are more consistent with an
odds ratio of 1.7 (95% CI 0.4–5.0) in favour of BRCA1 or BRCA2
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Table 2 Clinical characteristics of breast cancer patients carrying BRCA1 or BRCA2 mutations 
Mutation Age at diagnosis Family history  Histology Treatment Course of disease Follow up 
(1˚ and 2˚ relatives)
Bilateral breast cancer
1 BRCA 1 46 ys and 48 ys none BC 1: multifocal invasive-ductal,EIC BCT: BC 1 and 2 BC 1: local failure after 25 mo. 42 mo. 
517delTG CTX:BC 2 
recurr. BC 1: invasive-ductal HT: BC 1 
BC 2: invasive-ductal RT: BC 1 and 2 
2a BRCA2 54 ys and 59 ys BC: 1 (bilat., 2b) BC 1: invasive-ductal BCT: BC 1 and 2 NED 17 mo. 
4772delA BC 2: invasive-ductal RT: BC 1 and 2 
HT: BC 1 and 2 
2b BRCA2 73 ys (synchr.) BC: 1 (bilat., 2a) BC 1: invasive-lobular mastectomy: BC 1 BC 1: local failure after 64 mo. 76 mo., 
4772delA recurr. BC1: invasive-ductal BCT: BC 2 distant failure after 70 mo. deceased 
BC 2: invasive-tubular RT: BC 1, BC 2 
and recurr. BC 1 
HT: BC 1, BC 2, 
and recurr. BC 1 
3 BRCA 2 63 ys and 65 ys none BC 1: microinvasive-ductal BCT: BC 1 and 2 NED 9 mo. 
5946delCT BC 2: invasive-ductal RT: BC 1 and 2 
HT: BC 1 and 2 
4 BRCA 2 29 ys (synchr.) none BC 1: multifocal invasive-ductal BCT: BC 1 and 2 distant failure after 4 mo. 6 mo., 
6174delT BC 2: invasive-ductal CTX deceased 
RT: BC 1 and 2 
5 BRCA 2 46 ys and 59 ys BC: 2 BC 1: invasive–lobular BCT: BC 1 and 2 BC 1: local failures after 43 10 mo. 
8138del5 recurr.: invasive-ductal RT: BC 1 and 2 mo., 
BC 2: multifocal tubular HT: BC 1 and 2 57 mo. and 133 mo. 
Unilateral brest cancer
6 BRCA 1 Cys61 Gly 49 ys OC: 1 medullary BCT, CTX, RT NED 45 mo. 
7 BRCA 1  54 ys BC: 3 multifocal invasive-ductal mastectomy, CTX,  local failure  24 mo., 
3814del5 HT, RT (after local failure) after 9 mo. deceased
8 BRCA 1 5382insC 42 ys BC: 1 (bilat.) invasive-ductal BCT, CTX, RT NED 49 mo. 
Abbreviations: BCT = breast conservative therapy; RT = radiotherapy; CTX = chemotherapy, HT = hormonal therapy; BC = breast cancer; OC = ovarian cancer; NED = no evidence of disease, EIC = extensive
intraductal component. Patients 2a and 2b are daughter and mother, respectively. 
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mutation carriers in bilateral breast cancer. Although the confi-
dence intervals are wide and the results have to be confirmed with
larger sample sizes, the identification of only 5 mutation carriers
among 75 patients with bilateral breast cancer suggests that the
carrier frequency in our hospital-based sample may be about two-
or threefold lower than expected from multi-case family studies.
An important difference between population-based association
studies and family-based studies lies in the fact that the magnitude
of relative risks in the latter is conditional on shared genetic and
environmental influences. It is therefore possible that the high
frequency of bilateral disease in multi-case breast cancer families
may be due to a familial aggregation of other susceptibility factors
modifying the penetrance of BRCA1 and BRCA2 mutations. Such
a view would be supported by the recent observation that within
BRCA1 families the contralateral breast cancer risk is also associated
with the age at onset of the primary tumour (Verhoog et al, 2000). 
These apparent differences between family-based and popula-
tion-based studies may have implications for therapeutic decision
making. For instance, it has been proposed that the magnitude of
life expectancy gains from cancer prevention strategies, including
prophylactic contralateral mastectomy, strongly depends on the
penetrance of the BRCA mutation (Schrag et al, 2000). Our results
suggest that the penetrance with regard to contralateral disease is –
at least in our hospital-based sample – not necessarily a feature
determined only by the nature or location of the BRCA mutation
itself, as the mutational types and frequencies were similar in our
patients with unilateral and bilateral breast cancer. There may be
additional, yet undetermined, factors that influence the contralat-
eral breast cancer risk. Some of the known putative genetic modi-
fiers include ATM mutations, rare H-ras alleles or androgen
receptor gene variations (Phelan et al, 1996; Larson et al, 1998;
Rebbeck et al, 1999; Broeks et al, 2000). We have presently no
evidence that bilaterality of breast cancer alone were a strong indi-
cator of BRCA1 and BRCA2 mutations if adjusted for age and
family history. 
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APPENDIX 
Table A1 Primers used for the genomic PCR amplification of BRCA1 and BRCA2 gene segments 
Exon Forward primer Reverse primer Annealing (˚C) Size (bp) 
BRCA1
2 GTGTTAAAGTTCATTGGAACAG GCATAGGAGATAATCATAGGAATCC 58 162 
3 TGAGGCCTTATGTTGACTCAG CTGGGTTATGAAGGACAAAAAC 62 220 
5 CTCTTAAGGGCAGTTGTGAG TTCCTACTGTGGTTGCTTCC 64 234 
6 GGTTGATAATCACTTGCTGAG GCAAACTTCCTGAGTTTTCATG 62 200 
7 GCATACATAGGGTTTCTCTTGG AGAAGAAGAAGAAAACAAATGG 59 258 
8 CTGGCCAATAATTGCTTGACTG CTATAAGATAAGGAATCCAGC 60 207 
9 GTTGAATATCTGTTTTTCAAC CCAGCTTCATAGACAAAGGTTC 62 172 
10 TTGACAGTTCTGCATACATG AGGTCCCAAATGGTCTTCAG 62 232 
11/F CACCTCCAAGGTGTATGAAG CTCTAGGATTCTCTGAGCATGG 58 506 
11/1 CCAAAGCGAGCAAGAGAATCTC ATGAGTTGTAGGTTTCTGCTGTG 63 1337 
11/2 ACAATTCAAAAGCACCTAAAAAG* AACCCCTAATCTAAGCATAGCATTC 63 1463 
11/3 CACCACTTTTTCCCATCAAGTC* TTATTTTCTTCCAAGCCCGTTCC 63 1123 
11/R CTACTAGGCATAGCACCGTTGC CACTTCTATAAATAGACTGGG 58 419 
12 AAGACACAGCAAGTTGCAGCG GGGATACATACTACTGAATGC 64 224 
13 TAATGGAAAGCTTCTCAAAG TCCTTACTCTTCAGAAGGAG 58 306 
14 TCACTATCAGAACAAAGCAG GATGTCAGATACCACAGCATC 58 220 
15 TGCCCAGCAAGTATGATTTG TTGTTCCAATACAGCAGATG 59 289 
16 CTTAACAGAGACCAGAACTTTG GTCATTAGGGAGATACATATGG 58 415 
17 GTGTGCTAGAGGTAACTCATG GCAGCAGATGCAAGGTATTC 58 177 
18 TCTTAGGACAGCACTTCCTG CTGAGGTGTTAAAGGGAGGAG 64 190 
19 AGCACGTTCTTCTGCTGTATG TCTGGTTAGTTTGTAACATC 58 120 
20 TCTCTTATCCTGATGGGTTG GGGAATCCAAATTACACAGC 62 338 
21 CATCAGGTGGTGAACAGAAG GTAAGACAAAGGCTGGTGCTG 64 243 
22 GGTAGAGGGCCTGGGTTAAG CAGGTGCCAGTCTTGCTCAC 64 208 
23 TCCAGTAGTCCTACTTTGAC ACCCCATATAGCACAGGTAC 60 149 
24 GATTGATTAGAGCCTAGTCCAGG CAGCCTGAATAGAAAGAATAGGGC 64 519 
BRCA2
2 TATTTACCAAGCATTGGAGG TAGAAAACACTTTCTCGGTG 64 156 
3 ACAAATTTGTCTGTCACTGG GTAGTTCTCCCCAGTCTACC 64 338 
4 TCATTCCCAGTATAGAGGAG CTTCTACCAGGCTCTTAGCC 59 329 
5/6 AAGATAAACTAGTTTTTGCCAG GGGCAAAGGTATAACGCTATTGTC 56 328 
7 ATATCCTTAATGATCAGGGC GAGATGACAATTATCAACCTC 59 231 
8 GTAATCAAATAGTAGATGTGC TGTTAGCAATTTCAACAGTC 59 190 
9 AAGTGAAACCATGGATAAGGG CACGGGAGGCAGAGGTTGCGG 61 322 
10/F TCTATGAGAAAGGTTGTGAG CAAAGACGGTACAACTTCCTTG 59 418 
10 TATACTTTAACAGGATTTGG*˚ ACACAGAAGGAATCGTCATC 53 1116 
11/F CTTCCTGCCTCAGCCTCCCAAAAG GCTAGTTAAGGACAAAGTTGG 58 154 
11/1 TTTTTATGTTTAGGTTTATT*˚ TGCATTCCTCAGAAGTGGTC 57 1569 
11/2 AAACCAAGCTACATATTGC*˚ TAATTTCCTACATAATCTGCAG 59 1751 
11/3 TGGCTTAGAGAAGGAATAT*˚ AAAATAGTGATTGGCAACACG 63 1769 
12 AATGGTCTATAGACTTTTGAG ATCCATACCTATAGAGGGAG 59 218 
13 ACAGTAACATGGATATTCTC ACGAGACTTTTCTCATACTG 59 187 
14 TGAGGGTCTGCAACAAAGGC CAGGACATTATTTAACAACGG 64 573 
15 GTGCCTGGCCAGGGGTTGTGC CTCTGTCATAAAAGCCATCAG 60 281 
16 ATTGTGTGATACATGTTTAC GTTCGAGAGACAGTTAAGAG 59 322 
17 TTCAGTATCATCCTATGTGG TACTGCCGTATATGATTACG 59 267 
18 ACAGTGGAATTCTAGAGTCAC TTTAACTGAATCAATGACTG 56 460 
19 AAGGCAGTTCTAGAAGAATG AAGAGACCGAAACTCCATATC 54 339 
20 CCACTGTGCCTGGCCTGATAC GTCTCTAAGACTTTGTTCTC 64 283 
21 CTTTGGGTGTTTTATGCTTG CTTGAATAATCATCAAGCCTC 59 251 
22 CCATCTAGTTACAATAGATG ATCATTTTGTTAGTAAGGTC 54 339 
23 GATAATCACTTCTTCCATTGC TAAACTAACAAGCACTTATC 54 260 
23/24 GATAATCACTTCTTCCATTGC AACTGGTAGCTCCAACTAATC 64 531 
25 GGCATATTAGAGTTTCCTTTC CAAAATGTGTGGTGATGCTG 64 361 
26 CATCGGCATGTTTGACAATTGG CATTTTTACCATGTTTACTAGG 56 390 
27 TAGGGGAGGGAGACTGTGTG AACTGGAAAGGTTAAGCGTC 64 779 
*/*˚ A T7 promotor and a eukaryotic translation initiation sequence with an ATG start codon were added at the 5′ -end for further use of this primer in a protein
truncation test. 
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Table A4a Restriction-enzyme based mutation screening assays 
Gene/Exon Primer pair Size (bp) Annealing Substitution Enzyme Fragments 
BRCA1/5 BR5F/BR5R 234 64 Cys61Gly AvaII Cys 234, Gly 154/80 
BRCA1/11 BS1/BS2 1337 63˚C Gln356Arg Alw NI  Gln 396/941, Arg 1337 
BRCA1/11 BS5/BS4 325 59˚C Glu1038Gly Nla IV Glu 325, Gly 172/153 
BRCA1/11 BS5/BS4 325 59˚C Ser1040Asn AluI  Ser 178/147, Asn 325 
BRCA1/11 BS5B/R1347G 341 60˚C Arg1347Glu BsuF5/EcoNI Arg 189/152, Glu 189/134/18 
BRCA1/15 BR15F2/BR15S-I 145 64˚C Ser 1511 ile Alw NI Ser 145, ile 125/20 
BRCAI/16 BR16F/BR16R 415 58˚C Ser1613Gly AvaII, ScrFI, NlaIV Ser 415, Gly 179/236 
BRCA1/20 BS9/BS10 270 60˚C 5382insC ScrFI, wildtype 270, mutant 248/22 
DdeI wildtype 214/22, mutant 236 
BRCA2/10 BS11/1342D 359 56˚C Asn372His NlaIII Asn 359, His 334/25 
BRCA2/10 BS11/1342D 359 56˚C Asn289His NlaIII, Afl III Asn 359, His 274/85 
BRCA2/11 BS14/3624D 111 54˚C A3624G MwoI A 111, G 86/25 
BRCA2/11 BS15/16 1751 59˚C Serl172Leu Taq Leu 1751, Ser 1630/121 
BRCA2/11 BS16B/4035D 361 56˚C T4035C Tth IIII T 361, C 336/25 
BRCA2/11 BS19/18B 436 59˚C Thr1915Met NsiI Thr 436, Met 325/111 
BRCA2/11 6174delT/BS20A 375 61˚C 6174delT Pfl MI mutant 375, wildtype 354/21 
BRCA2/18 BR2-18F/V2728I-R 286 60˚C Val2728lle HpaI Val 265/21, Ile 286 
Table A4b Sequences of mismatch primers used in restriction-enzyme based screening assays 
Gene/Exon Gene alteration Designation Sequence (5′ -3′ , mismatch) Use in Table 4a 
BRCA1/11 A4158G R1347G-R ATTTTCTTCCAAGCCCGTTCATC Reverse primer 
BRCA1/15 G4654T BR15-S/I CTATTCTGAAGACTCCCACAGC Reverse primer 
BRCA1/20 5382insC BS10 CCAAAGCGAGCAAGAGAATCTC Forward primer 
BRCA2/10 C1342A 1342D CTTCCACTCTCAAAGGGCTTCTCAT Reverse primer 
BRCA2/11 A3624G 3624D GTCAGTTTGAATTTACTCAGCTTAG Forward primer 
BRCA2/11 T4035C 4035D TCTTCAAGTTTTTGTCATGACTCTG Forward primer 
BRCA2/11 6174delT 6174delT GTGGGATTTTTAGCCCAGCAAG Forward primer 
BRCA2/18 G8410A V2728I-R GGGAGGATCTAACTGGGCGTTAA Reverse primer 
Table A3 Restriction fragments for SSCP analysis 
Gene/Exon Restriction enzyme Size of fragments (bp) 
1/11 F EcoRI 187/319 
1/11/1 Alw I, HphI 363/270/372/332 
1/11/2 DdeI 238/207/225/306/383 
1/11/3 FokI, EcoNI 358/371/186/208 
1/11R EcoNI 135/284 
1/16 MboI 131/284 
1/24 MboI 173/346 
2/10F NlaIII 171/289 
2/10 DpnII, BsaAI 297/250/236/333 
2/11/1 HphI, SpeI 297/316/290/306/360 
2/11/2 PstI, Bcl I, BsaI, Scr FI 366/318/273/169/216/389 
2/11/3 HphI, BsaAI 379/384/272/175/273/294 
2/14 DraI 303/270 
2/18 DdeI 290/170 
2/23+24 MspI 208/323 
2/26 DpnII 213/177 
2/27 Drd I/NlaIV/MboI 218/169/257/133 
Table A2 Duplex PCR conditions 
Gene/Exon Annealing (˚C) Primer ratio 
BRCA 1/9 + 20 60 3:1 
BRCA 2/2 + 3 62 1:1 
BRCA 2/4 + 12 57 1:1 
BRCA 2/7 + 8 59 1:1 
BRCA 2/13 + 17 57 1:1 
BRCA 2/16 + 21 57 1:1
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